The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Phase I Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results
Abstract
Purpose: Advances in brain tumor biology indicate that transfer of p53 is an alternative therapy for human gliomas. Consequently, we undertook a phase I clinical trial of p53 gene therapy using an adenovirus vector (Ad-p53, INGN 201). Materials and Methods: To obtain molecular information regarding the transfer and distribution of exogenous p53 into gliomas after intratumoral injection and to determine the toxicity of intracerebrally injected Ad-p53, patients underwent a two-stage approach. In stage 1, Ad-p53 was stereotactically injected intratumorally via an implanted catheter. In stage 2, the tumor-catheter was resected en bloc, and the postresection cavity was treated with Ad-p53. This protocol provided intact Ad-p53–treated biologic specimens that could be analyzed for molecular end points, and because the resection cavity itself was injected with Ad-p53, patients could be observed for clinical toxicity. Results: Of fifteen patients enrolled, twelve underwent both treatment stages. In all patients, exogenous p53 protein was detected within the nuclei of astrocytic tumor cells. Exogenous p53 transactivated p21 CIP/WAF and induced apoptosis. However, transfected cells resided on average within 5 mm of the injection site. Clinical toxicity was minimal and a maximum-tolerated dose was not reached. Although anti-adenovirus type 5 (Ad5) titers increased in most patients, there was no evidence of systemic viral dissemination. Conclusion: Intratumoral injection of Ad-p53 allowed for exogenous transfer of the p53 gene and expression of functional p53 protein. However, at the dose and schedule evaluated, transduced cells were only found within a short distance of the injection site. Although toxicity was minimal, widespread distribution of this agent remains a significant goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Self-citationFunctional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms
Kelly, P. J., Daumas-Duport, C., Kispert, D. B., Kall, B. A., Scheithauer, B. W., & Illig, J. J. (1987) · Journal of Neurosurgery · doi:10.3171/jns.1987.66.6.0865 · Cited by 798
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.763 · Cited by 496
Epidemiology of brain tumors: The national survey of intracranial neoplasms
Walker, A. E., Robins, M., & Weinfeld, F. D. (1985) · Neurology · doi:10.1212/wnl.35.2.219 · Cited by 487
Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romano, J. W., & Ullrich, S. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.16.6166 · Cited by 477
KELLY, P. J., DAUMAS-DUPORT, C., SCHEITHAUER, B. W., KALL, B. A., & KISPERT, D. B. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)65470-6 · Cited by 403
Clayman, G. L., el-Naggar, A. K., Lippman, S. M., Henderson, Y. C., Frederick, M., Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2221 · Cited by 371
Nemunaitis, J., Swisher, S. G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D. D., Kemp, B. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.609 · Cited by 322
Lang, F. F., Miller, D. C., Koslow, M., & Newcomb, E. W. (1994) · Journal of Neurosurgery · doi:10.3171/jns.1994.81.3.0427 · Cited by 300
Self-citationExpression of p53 and Prognosis in Children with Malignant Gliomas
Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J., Holmes, E. J., Hamilton, R. L., Yates, A. J., Boyett, J. M., Finlay, J. L., & Sposto, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012224 · Cited by 281
Frankel, R. H., Bayona, W., Koslow, M., & Newcomb, E. W. (1992) · PubMed · Cited by 238
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. J., Steck, K. D., Levin, V. A., & Yung, W. K. A. (1996) · PubMed · Cited by 228
Self-citationGelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1281 · Cited by 204
The p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
Spitz, F. R., Nguyen, D. N., Skibber, J. M., Meyn, R. E., Cristiano, R. J., & Roth, J. A. (1996) · PubMed · Cited by 179
Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
Parr, M. J., Manome, Y., Tanaka, T., Wen, P., Kufe, D. W., Kaelin, W. G., & Fine, H. A. (1997) · Nature Medicine · doi:10.1038/nm1097-1145 · Cited by 169
Characterization of p53 and p21 Functional Interactions in Glioma Cells en Route to Apoptosis
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Levin, V. A., Yung, W. K. A., & McDonnell, T. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1036 · Cited by 142
Self-citationGermline p53 Gene Mutations in Subsets of Glioma Patients
Kyritsis, A. P., Bondy, M. L., Xiao, M., Berman, E. L., Cunningham, J. E., Lee, P. S., Levin, V. A., & Saya, H. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.5.344 · Cited by 136
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90014-0 · Cited by 134
Lang, F. F., Miller, D. C., Pisharody, S., Koslow, M., & Newcomb, E. W. (1994) · PubMed · Cited by 124
Self-citationSafety Evaluation of Ad5CMY- p53 In Vitro and In Vivo
Zhang, W., Alemany, R., Wang, J., Koch, P. E., Ordóǹez, N. G., & Roth, J. A. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.2-155 · Cited by 119
Roth, J. A., Swisher, S. G., Merritt, J. A., et al. (1998) · PubMed · Cited by 112
Louis, D. N., Rubio, M., Correa, K. M., Gusella, J. F., & von Deimling, A. (1993) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199309000-00009 · Cited by 102
Adenovirus-mediated p53 Gene Therapy for Human Gliomas
Lang, F. F., Yung, W. K. A., Sawaya, R. A., & Tofilon, P. J. (1999) · Neurosurgery · doi:10.1097/00006123-199911000-00016 · Cited by 95
Self-citationPhase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism
Eisenhauer, E. A. (1998) · Annals of Oncology · doi:10.1023/a:1008497110734 · Cited by 95
Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma.
Li, H., Alonso‐Vanegas, M., Colicos, M. A., Jung, S.-M., Lochmüller, H., Sadikot, A. F., Snipes, G. J., Seth, P. K., Karpati, G., & Nalbantoglu, J. N. (1999) · PubMed · Cited by 91
p53 and Brain Tumors: From Gene Mutations to Gene Therapy
Fulci, G., Ishii, N., & Meir, E. G. V. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00187.x · Cited by 89
p53 tumor suppressor gene therapy for cancer.
Roth, J. A., Swisher, S. G., & Meyn, R. E. (1999) · PubMed · Cited by 86
Lang, F. F., Yung, W. K. A., Raju, U., Libunao, F., Terry, N. H. A., & Tofilon, P. J. (1998) · Journal of neurosurgery · doi:10.3171/jns.1998.89.1.0125 · Cited by 83
Self-citationShono, T., Tofilon, P. J., Schaefer, T. S., Parikh, D., Liu, T.-J., & Lang, F. F. (2002) · PubMed · Cited by 80
Self-citationClinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies
Merritt, J. A., Roth, J. A., & Logothetis, C. J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90288-x · Cited by 74
Smith, J. G., Raper, S. E., Wheeldon, E. B., Hackney, D. B., Judy, K. D., Wilson, J. M., & Eck, S. L. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.8-943 · Cited by 59
In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Modesitt, S. C., Ramirez, P. T., Zu, Z., Bodurka, D. C., Gershenson, D. M., & Wolf, J. K. (2001) · PubMed · Cited by 47
Familial Brain Tumour Syndrome Associated with a p53 Germline Deletion of Codon 236
Lübbe, J., Ammon, K. V., Watanabe, K., Hegi, M. E., & Kleihues, P. (1995) · Brain Pathology · doi:10.1111/j.1750-3639.1995.tb00572.x · Cited by 32
Detection of p21WAF1/Cip1 in brain metastases
Ruan, S., Fuller, G. N., Levin, V. A., Bruner, J. M., & Zhang, W. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005972808311 · Cited by 11
Self-citationCellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1874 · Cited by 1,035
Self-citationChiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Self-citationCurrent Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1271 · Cited by 341
Metadata
- Authors
- Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., Chandler, W., Zwiebel, J. A., Kaplan, R. S., & Yung, W. K. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-07-01
- Volume
- 21
- Issue
- 13
- Pages
- 2508-2518
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3022598401
- Cited by
- 395
- References
- 40
- FWCI
- 16.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.